Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.35.

Segment Revenue

• Research and Development Expenses: $2,848,544 for the three months ended September 30, 2025, compared to $1,428,504 for the same period in 2024, representing a 99.5% increase.
• General and Administrative Expenses: $3,147,291 for the three months ended September 30, 2025, compared to $1,853,583 for the same period in 2024, representing a 69.7% increase.

Operational Metrics

• Net Loss: $7,341,062 for the three months ended September 30, 2025, compared to $4,125,643 for the same period in 2024, representing a 77.9% increase.
• Operating Loss: $5,995,835 for the three months ended September 30, 2025, compared to $3,282,087 for the same period in 2024, representing an 82.7% increase.

Cash Flow

• Net Cash Used in Operating Activities: $13,647,893 for the nine months ended September 30, 2025, compared to $14,371,857 for the same period in 2024.
• Net Cash Provided by Financing Activities: $7,561,207 for the nine months ended September 30, 2025, compared to $24,372,928 for the same period in 2024.

Unique Metrics

• Issuance Cost and Change in Fair Value of Derivative: $772,169 for the three months ended September 30, 2025, compared to $894,039 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to seek regulatory approval for CTx-1301 and continue research and development activities for existing and new product candidates, primarily CTx-1301.
• Non-Core Business: The company is evaluating additional therapeutic areas where its PTR technology may be employed to develop future product candidates.
• Priority: The company believes it will need to raise approximately $9 million of additional capital to advance its commercialization efforts for CTx-1301 through its PDUFA date of May 31, 2026.